Hand and foot eczema might sound minor, but for the people living with it, the constant itch, pain, and visible lesions can make everyday tasks — typing, walking, cooking — genuinely difficult. Now, a phase 3b trial called ADTouch offers real hope: lebrikizumab (Ebglyss, Lilly), a selective IL-13 inhibitor, significantly outperformed placebo across every key measure of the disease.

The trial enrolled 221 adolescents and adults with moderate-to-severe atopic hand and foot dermatitis. Participants received either lebrikizumab (500 mg loading dose, then 250 mg every 2 weeks) or placebo for 16 weeks. The results were striking — and fast.

By the Numbers:

• 53.3% of lebrikizumab patients hit the primary endpoint (skin clearance) vs. 27.2% on placebo
• 57.1% achieved meaningful itch relief by week 16 vs. 19% on placebo
• 59.1% saw significant pain reduction vs. 18.8% on placebo
• 76.7% reported satisfaction with clearance vs. 39.6% on placebo
• Itch improvements were detectable as early as week 2

Why it matters: These findings push dermatology toward a more nuanced view of disease severity — where location matters as much as extent. Patients with limited body surface area involvement can still carry a heavy quality-of-life burden, and lebrikizumab's consistent benefit across skin clearance, itch, pain, and patient satisfaction marks a meaningful step forward for this underserved group.